For the quarter ending 2026-03-31, BBLG had -$804,282 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 141,597 | 257,197 | 187,808 | - |
| Salaries | 125,000 | 275,000 | 125,000 | - |
| Insurance | 68,919 | 70,369 | 214,970 | - |
| Stock-based compensation | 23,505 | 45,674 | 87,180 | - |
| Operating expenses | 445,768 | 88,334 | 242,297 | - |
| Interest income | 38,801 | 51,931 | 47,325 | - |
| Net loss | -765,988 | -684,643 | -666,737 | -1,757,611 |
| Stock-based compensation | 23,505 | 45,674 | 87,180 | 123,504 |
| Change in fair value of warrant liability | -265 | -498 | -1,212 | -2,257 |
| Research and development contract liabilities | - | - | - | 0 |
| Advances on research and development contract services | - | 11,314 | -11,314 | 49,087 |
| Prepaid insurance | -62,419 | -35,233 | - | - |
| Interest receivable | -2,086 | 9,895 | - | - |
| Prepaid insurance and prepaid expenses | - | - | -71,347 | -125,403 |
| Prepaid financing costs | 51,957 | - | - | - |
| Accrued legal settlement | - | - | - | 0 |
| Accounts payable and accrued expenses | -74,082 | 84,803 | -70,648 | 76,870 |
| Net cash used in operating activities | -804,282 | -714,762 | -591,384 | -1,385,004 |
| Exercise of pre-funded warrants | - | - | - | 0 |
| Proceeds from issuance of common shares from atm, net of costs | - | 0 | 0 | 347,549 |
| Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs | - | 0 | 0 | 4,352,792 |
| Net cash provided by financing activities | - | 0 | 0 | 4,700,341 |
| Net decrease in cash | -804,282 | -714,762 | -591,384 | 3,315,337 |
| Cash, beginning of period | 5,334,322 | 6,049,084 | 3,325,131 | - |
| Cash, end of period | 4,530,040 | 5,334,322 | 6,049,084 | - |
Bone Biologics Corp (BBLG)
Bone Biologics Corp (BBLG)